191 related articles for article (PubMed ID: 24652413)
21. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.
Lai YS; Cheng CC; Lee MT; Chao WT; Lai YC; Hsu YH; Liu YH
Int J Med Sci; 2018; 15(14):1746-1756. PubMed ID: 30588199
[No Abstract] [Full Text] [Related]
22. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.
Maeda T; Adachi E; Kajiyama K; Sugimachi K; Tsuneyoshi M
Hum Pathol; 1995 Sep; 26(9):956-64. PubMed ID: 7545644
[TBL] [Abstract][Full Text] [Related]
23. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma.
Gu MJ; Jang BI
Pathol Oncol Res; 2014 Jul; 20(3):655-60. PubMed ID: 24482053
[TBL] [Abstract][Full Text] [Related]
25. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
Batmunkh E; Tátrai P; Szabó E; Lódi C; Holczbauer A; Páska C; Kupcsulik P; Kiss A; Schaff Z; Kovalszky I
Hum Pathol; 2007 Oct; 38(10):1508-15. PubMed ID: 17640714
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
Terada T; Nakanuma Y; Sirica AE
Hum Pathol; 1998 Feb; 29(2):175-80. PubMed ID: 9490278
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs.
Harada K; Sato Y; Ikeda H; Maylee H; Igarashi S; Okamura A; Masuda S; Nakanuma Y
Virchows Arch; 2012 Mar; 460(3):281-9. PubMed ID: 22358181
[TBL] [Abstract][Full Text] [Related]
29. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Sia D; Villanueva A; Friedman SL; Llovet JM
Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
[TBL] [Abstract][Full Text] [Related]
30. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
[TBL] [Abstract][Full Text] [Related]
31. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
Tischoff I; Tannapfel A
Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
[TBL] [Abstract][Full Text] [Related]
32. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver.
Kozyraki R; Scoazec JY; Flejou JF; D'Errico A; Bedossa P; Terris B; Fiorentino M; Bringuier AF; Grigioni WF; Feldmann G
Gastroenterology; 1996 Apr; 110(4):1137-49. PubMed ID: 8613003
[TBL] [Abstract][Full Text] [Related]
33. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma.
Tanaka Y; Aishima S; Kohashi K; Okumura Y; Wang H; Hida T; Kotoh K; Shirabe K; Maehara Y; Takayanagi R; Oda Y
Histopathology; 2016 Apr; 68(5):693-701. PubMed ID: 26267070
[TBL] [Abstract][Full Text] [Related]
34. Nucleolar organizer regions in cirrhosis and hepatocellular carcinoma.
Jain R; Malhotra V; Kumar N; Sarin SK
Trop Gastroenterol; 1998; 19(3):100-1. PubMed ID: 9828706
[TBL] [Abstract][Full Text] [Related]
35. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.
Terada T; Ashida K; Endo K; Horie S; Maeta H; Matsunaga Y; Takashima K; Ohta T; Kitamura Y
Histopathology; 1998 Oct; 33(4):325-31. PubMed ID: 9822921
[TBL] [Abstract][Full Text] [Related]
36. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
37. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
[TBL] [Abstract][Full Text] [Related]
38. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
[TBL] [Abstract][Full Text] [Related]
39. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
40. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
